Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 75,000 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 75,000 shares of the business’s stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $79.99, for a total value of $5,999,250.00. Following the completion of the transaction, the director directly owned 701,477 shares of the company’s stock, valued at approximately $56,111,145.23. The trade was a 9.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Liquidia Trading Up 2.8%

Shares of NASDAQ LQDA opened at $86.82 on Wednesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The stock has a market capitalization of $7.72 billion, a P/E ratio of 620.19 and a beta of 0.55. Liquidia Corporation has a 1-year low of $16.82 and a 1-year high of $91.10. The business has a fifty day moving average price of $72.31 and a 200 day moving average price of $50.98.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The company’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Equities research analysts expect that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Liquidia

Several institutional investors and hedge funds have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia in the 4th quarter valued at $25,000. Covestor Ltd raised its stake in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the last quarter. NewEdge Advisors LLC acquired a new stake in Liquidia during the 2nd quarter worth about $25,000. Fluent Financial LLC acquired a new position in shares of Liquidia in the second quarter valued at about $287,000. Finally, Fulcrum Equity Management acquired a new position in shares of Liquidia in the second quarter valued at about $399,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. HC Wainwright set a $36.00 price objective on shares of Liquidia in a research note on Friday. Stephens set a $130.00 price target on shares of Liquidia in a report on Friday. Royal Bank Of Canada set a $130.00 price target on Liquidia in a research report on Friday. Oppenheimer set a $75.00 price objective on Liquidia in a report on Friday, June 5th. Finally, Bank of America reissued a “neutral” rating and issued a $79.00 price objective (up from $64.00) on shares of Liquidia in a research report on Monday, June 29th. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Liquidia currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.18.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: LifeSci Capital maintained its Buy rating on Liquidia, supporting the bullish view of the company’s outlook. LifeSci Capital Sticks to Their Buy Rating for Liquidia
• Positive Sentiment: HC Wainwright expressed a positive view of Liquidia’s fiscal 2027 earnings prospects, suggesting analysts expect meaningful future growth. HC Wainwright Has Positive View of Liquidia FY2027 Earnings
• Positive Sentiment: Buckley Capital Advisors said Liquidia could have more than 50% upside, citing the upcoming YUTREPIA ruling and potential buyout interest. This reinforces the importance of regulatory and strategic catalysts for LQDA. Liquidia Has 50% Plus Upside on YUTREPIA Ruling and Buyout Potential
• Neutral Sentiment: Recent valuation coverage highlights a debate between YUTREPIA-driven growth and patent risk. Another analysis argues the stock still looks expensive as YUTREPIA expansion progresses, indicating that further appreciation depends on execution and successful intellectual-property outcomes. Liquidia Rallies as Fair Value Debate Turns on Growth and Patent Risk Liquidia Stock Still Looks Expensive
• Negative Sentiment: Director Stephen M. Bloch disclosed three sales totaling 178,596 shares for approximately $15.2 million between July 20 and July 23. Although he retained a substantial position, the sizable reduction could weigh on sentiment because it signals insider profit-taking after LQDA’s strong run. SEC Insider Transaction Filing

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).